Choosing the right anti-platelet duration for advanced kidney disease
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at the best length of anti-platelet medicine (which helps prevent stent clots) after a new type of heart stent. It specifically focuses on people with advanced chronic kidney disease, where bleeding and clot risks can be higher.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are older than 19 years
- You have advanced chronic kidney disease (stage IIIb, IV, or V, or you are on dialysis)
- You received a new-generation drug-eluting stent
- You signed an informed consent form
- You are 85 years old or younger
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special ultrasound camera inside the heart's arteries to guide stent placement for people with chronic kidney disease. The goal is to see if this approach improves outcomes compared to standard methods.
This trial compares two types of blood thinners (vitamin K antagonists and factor Xa inhibitors) versus no blood thinner in people with atrial fibrillation who are on dialysis or have very advanced kidney disease. It aims to see which option is safest and most effective for preventing strokes and bleeds.
This trial tests whether tailoring anti-platelet (blood clot prevention) treatment can better protect people at higher risk of heart or blood-vessel problems after a drug-eluting stent. It may help prevent future clots and complications, especially in patients with certain high-risk health conditions or complex stent/scar tissue features.
This trial is testing a way to shorten the time you need to take blood thinners after getting a specific type of heart stent. It uses a special camera (OCT) inside the artery to help decide if stents are placed well enough to allow less time on dual antiplatelet therapy.
This trial looks at the best blood-thinning (antiplatelet) plan after a left atrial appendage closure procedure in people with kidney failure on dialysis. It may help reduce stroke risk while also lowering medicine-related side effects.
This trial tests if a very short course of dual antiplatelet therapy (two blood thinners) after getting a stent is safe and effective for patients aged 65 and older. The goal is to reduce bleeding risks while still preventing heart attacks.
Hear when a new Chronic Kidney Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.